Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?
Why Is Diabetes Focused Creative Medical Stock Surging On Thursday?
Thursday, Creative Medical Technology Holdings Inc (NASDAQ:CELZ) secured FDA authorization for an expanded access therapy using CELZ-201, a cell-based program to manage abnormal glucose tolerance and prevent Type 1 diabetes (T1D) in high-risk individuals.
The therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in medical history.
This personalized medicine approach focuses on a single high-risk patient.
CELZ-201 has a multi-target mechanism to address abnormal glucose tolerance, a T1D precursor, at the cellular level. It embodies hope for high-risk individuals, offering a proactive defense against T1D development.
The shares are trading on a higher session volume of 1.262 million compared to the average volume of 67.610K, as per the data from Benzinga Pro.
Wednesday, the FDA granted Orphan Drug Designation to Creative Medical's CELZ-101, ImmCelz, aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation, a significant advancement for individuals with Type 1 diabetes.
CELZ-101 represents an approach in personalized medicine, utilizing the patient's regulatory T cells (Tregs) to combat autoimmune and alloimmune responses that can destroy insulin-producing cells.
Price Action: CELZ shares are up 34.50% at $6.40 on the last check Thursday.
Photo by Towfiqu barbhuiya on Unsplash
Thursday, Creative Medical Technology Holdings Inc (NASDAQ:CELZ) secured FDA authorization for an expanded access therapy using CELZ-201, a cell-based program to manage abnormal glucose tolerance and prevent Type 1 diabetes (T1D) in high-risk individuals.
週四，Creative Medical Technology Holdings Inc（納斯達克股票代碼：CELZ）獲得了美國食品藥品管理局的授權，允許使用 CELZ-201 進行擴大准入療法，這是一項基於細胞的計劃，用於管理高危人群的異常葡萄糖耐量和預防1型糖尿病（T1D）。
The therapy uses CELZ-201 to potentially prevent T1D onset and is believed to be a first in medical history.
該療法使用 CELZ-201 有可能預防 T1D 的發作，據信是醫學史上的首例。
This personalized medicine approach focuses on a single high-risk patient.
這種個性化醫療方法側重於單個高風險患者。
CELZ-201 has a multi-target mechanism to address abnormal glucose tolerance, a T1D precursor, at the cellular level. It embodies hope for high-risk individuals, offering a proactive defense against T1D development.
CELZ-201 具有多靶點機制，可以在細胞層面上解決異常的葡萄糖耐量（T1D 前體）。它體現了高風險人群的希望，爲T1D的發展提供了積極的防禦。
The shares are trading on a higher session volume of 1.262 million compared to the average volume of 67.610K, as per the data from Benzinga Pro.
根據Benzinga Pro的數據，這些股票的交易量更高，爲126.2萬股，而平均交易量爲67.61萬股。
Wednesday, the FDA granted Orphan Drug Designation to Creative Medical's CELZ-101, ImmCelz, aimed at preventing allograft rejection in patients undergoing pancreatic islet cell transplantation, a significant advancement for individuals with Type 1 diabetes.
週三，美國食品藥品管理局授予Creative Medical的 CELZ-101 immcelZ孤兒藥稱號，旨在防止接受胰島細胞移植的患者出現同種異體移植排斥反應，這對於1型糖尿病患者來說是一項重大進步。
CELZ-101 represents an approach in personalized medicine, utilizing the patient's regulatory T cells (Tregs) to combat autoimmune and alloimmune responses that can destroy insulin-producing cells.
CELZ-101 代表了一種個性化醫療方法，利用患者的調節性 T 細胞 (Treg) 來對抗可能破壞產生胰島素的細胞的自身免疫和同種免疫反應。
Price Action: CELZ shares are up 34.50% at $6.40 on the last check Thursday.
價格走勢：在週四的最後一次支票中，CELZ股價上漲34.50％，至6.40美元。
Photo by Towfiqu barbhuiya on Unsplash
照片由 Towfiqu barbuiya 在 Unsplash
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧